Conclusions
LUNG CANCER
In a real‐world cohort, adjuvant durvalumab is safe and beneficial in a substantial proportion of patients who would not have been eligible for the PACIFIC trial.We focused on a cohort of 126 patients with stage III non‐small‐cell lung cancer and evaluated eligibility for the PACIFIC study and durvalumab on outcomes. A large proportion of our cohort were ineligible for the PACIFIC study (44%). Trial eligibility led to improved outcome regardless of receipt of durvalumab. However, durvalumab was also safe and beneficial in many patients who were ineligible for the PACIFIC trial. This data provides further evidence that durvalumab use is safe and beneficial in a real‐world setting.

